Skip to content
Open access · CC-BY via OpenAlex

Randomized controlled trial of once-per-week intermittent fasting for health improvement: the WONDERFUL trial

Ciera L. Bartholomew, Joseph B Muhlestein, Heidi T. May, Viet T. Le, Oxana Galenko, Kelly Davis Garrett, Cherie P. Brunker, Ramona O. Hopkins, John F. Carlquist, Kirk U. Knowlton, Jeffrey L. Anderson, Bruce W. Bailey, Benjamin D. Horne

European Heart Journal Open · 2021 · ▲ 35 citations

Abstract

Abstract Aims Low-density lipoprotein cholesterol (LDL-C) predicts heart disease onset and may be reduced by intermittent fasting. Some studies, though, reported that fasting increased LDL-C; however, no study evaluated LDL-C as the primary endpoint. This randomized controlled trial evaluated the effect of low-frequency intermittent fasting on LDL-C and other biomarkers. Methods and results Adults aged 21–70 years were enrolled who were not taking a statin, had modestly elevated LDL-C, had ≥1 metabolic syndrome feature or type 2 diabetes, and were not taking anti-diabetic medication (N = 103). Water-only 24-h fasting was performed twice weekly for 4 weeks and then once weekly for 22 weeks; controls ate ad libitum. The primary outcome was 26-week LDL-C change score. Secondary outcomes (requiring P ≤ 0.01) were 26-week changes in homeostatic model assessment of insulin resistance (HOMA-IR), Metabolic Syndrome Score (MSS), brain-derived neurotrophic factor (BDNF), and MicroCog general cognitive proficiency index (GCPi). Intermittent fasting (n = 50) and control (n = 53) subjects were, respectively, aged 49.3 ± 12.0 and 47.0 ± 9.8 years, predominantly female (66.0% and 67.9%), and overweight (103 ± 24 and 100 ± 21 kg) and had modest LDL-C elevation (124 ± 19 and 128 ± 20 mg/dL). Drop-outs (n = 12 fasting, n = 20 control) provided an evaluable sample of n = 71 (n = 38 fasting, n = 33 control). Intermittent fasting did not change LDL-C (0.2 ± 16.7 mg/dL) vs. control (2.5 ± 19.4 mg/dL; P = 0.59), but it improved HOMA-IR (−0.75 ± 0.79 vs. −0.10 ± 1.06; P = 0.004) and MSS (−0.34 ± 4.72 vs. 0.31 ± 1.98, P = 0.006). BDNF (P = 0.58), GCPi (P = 0.17), and weight (−1.7 ± 4.7 kg vs. 0.2 ± 3.5 kg, P = 0.06) were unchanged. Conclusions A low-frequency intermittent fasting regimen did not reduce LDL-C or improve cognitive function but significantly reduced both HOMA-IR and MSS. Trial registration clinicaltrials.gov, NCT02770313.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1093/ehjopen/oeab026
Canonical
link ↗
Fetched
2026-08-25 MST

Cite this

APA
Bartholomew, C.L., Muhlestein, J.B., May, H.T., Le, V.T., Galenko, O., Garrett, K.D., Brunker, C.P., Hopkins, R.O., Carlquist, J.F., Knowlton, K.U., Anderson, J.L., Bailey, B.W., &amp; Horne, B.D. (2021). Randomized controlled trial of once-per-week intermittent fasting for health improvement: the WONDERFUL trial. <em>European Heart Journal Open</em>. https://doi.org/10.1093/ehjopen/oeab026
Vancouver
Bartholomew CL, Muhlestein JB, May HT, Le VT, Galenko O, Garrett KD, et al. Randomized controlled trial of once-per-week intermittent fasting for health improvement: the WONDERFUL trial. European Heart Journal Open. 2021. doi:10.1093/ehjopen/oeab026.
BibTeX
@article{ciera2021Random, title = {Randomized controlled trial of once-per-week intermittent fasting for health improvement: the WONDERFUL trial}, author = {Ciera L. Bartholomew and Joseph B Muhlestein and Heidi T. May and Viet T. Le and Oxana Galenko and Kelly Davis Garrett and Cherie P. Brunker and Ramona O. Hopkins and John F. Carlquist and Kirk U. Knowlton and Jeffrey L. Anderson and Bruce W. Bailey and Benjamin D. Horne}, journal = {European Heart Journal Open}, year = {2021}, doi = {10.1093/ehjopen/oeab026}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings